Effect of a Diet Without Non-caloric Sweeteners on Gastrointestinal Symptoms in Patients With IBS and Dyspepsia (IBS)

October 14, 2019 updated by: Nallely Bueno Hernández, Hospital General de Mexico

Effect of a Diet Without Non-caloric Sweeteners on Gastrointestinal Symptoms in Patients With Irritable Bowel Syndrome and Dyspepsia

Digestive Functional Disorders (DFD), represent 50% of medical check ups, the symptoms interfere with patients quality of life and generate high health costs. On the other hand, with the worldwide overweight and obesity increase,causing an over production of low-calorie products, which increase the non-caloric sweeteners (NCS) consumption.

Hypothesis: A diet without NCS will reduce gastrointestinal symptoms in volunteers with dyspepsia and IBS.

Objective: To asses the effect of a diet without NCS, on the gastrointestinal symptoms in patients with dyspepsia and IBS.

Secondary Objectives: To compare the effect of a diet without NCS against a diet with NCS on anthropometry, changes in body composition, biochemical parameters, glucose and insulin. To asses the change in the gut microbiota using real-time PCR (polymerase chain reaction)

Methodology: it will be an experimental, open, parallel, controlled study lasting 12 weeks, patients with dyspepsia or IBS will be randomized assigned to a diet with or without NCS.

Laboratory studies, dietary and symptoms questionnaires, anthropometry measurements and faecal sample will be carried out.

Analysis Results: A double data capture will be carried out to minimize errors, for the statistical analysis of using the Statistical Package for the Social Sciences (SPSS) version 25, descriptive statistics will be used to report the baseline data of the volunteers. Using means and standard deviation, the variables of gastrointestinal symptoms will be used a chi-square test and a p <0.05 will be considered significant. Different analyzes will be done to evaluate volunteers with IBS and those with dyspepsia. For the intestinal microbiota analysis, a comparison will be made between the percentages of Firmicutes, Bacteroidetes and Actinobacteria of sample 1 and 2 and a chi-square test will be performed considering a p <0.05 significant

Study Overview

Detailed Description

Recruitment will be carried out in the gastroenterology service, where patients will have their diagnosis of IBS or dyspepsia, participants are invited to participate in the study to subsequently sign the informed consent.

Once signed the patient is scheduled for blood studies, their nutritional evaluation will be carried out and their menu will be delivered.

Patients will be followed for 12 weeks to re-conduct their nutritional evaluation and laboratory studies.

Study Type

Interventional

Enrollment (Anticipated)

140

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Cuauhtemoc
      • Mexico City, Cuauhtemoc, Mexico, 06720

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Both sexes from 18 to 65 years old
  • Diagnosis of IBS or Dyspepsia
  • Patients with dyspepsia must have endoscopy
  • Normal or overweight BMI (18.5 - 29.9 kg / m2)
  • Not suffering from chronic non-communicable or infectious diseases
  • Follow the meal plan that is being given.
  • Do not consume alcoholic beverages
  • No Smoking
  • Signing of the informed consent letter expressing your desire to participate as volunteers in the study

Exclusion Criteria:

  • People who at the time of their selection are studying with acute illness of any kind
  • Type 1 or 2 diabetes.
  • Diagnosis of malabsorption syndrome
  • Neoplasia
  • Inflammatory bowel disease
  • Medicine that affects the gastrointestinal tract
  • Women who at the time of their selection are pregnant or breastfeeding

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: SUPPORTIVE_CARE
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Diet without NCS in irritable bowl syndrome
Participants with irritable bowl syndrome are assigned to a 5 meals divided diet. In which it does not contain any products with NCS

A standard diet in terms of macronutrients will be calculated.

  • 55% Carbohydrates
  • 20% protein
  • 25% Lipids The energy calculation will be done with the Harris Benedict formula and a diet with equivalents will be made and then a menu distributed in 5 meals, lasting 7 days.

The menu will not contain products with NCS.

Other Names:
  • Diet
ACTIVE_COMPARATOR: Diet with NCS in irritable bowl syndrome
Participants with irritable bowl syndrome are assigned to a 5 meals divided diet. In which it contain any products with NCS

A standard diet in terms of macronutrients will be calculated.

  • 55% Carbohydrates
  • 20% protein
  • 25% Lipids The energy calculation will be done with the Harris Benedict formula and a diet with equivalents will be made and then a menu distributed in 5 meals, lasting 7 days.

The menu will contain products with NCS.

Other Names:
  • Diet
EXPERIMENTAL: Diet without NCS in dyspepsia
Participants with dyspepsia are assigned to a 5 meals divided diet. In which it does not contain any products with NCS

A standard diet in terms of macronutrients will be calculated.

  • 55% Carbohydrates
  • 20% protein
  • 25% Lipids The energy calculation will be done with the Harris Benedict formula and a diet with equivalents will be made and then a menu distributed in 5 meals, lasting 7 days.

The menu will not contain products with NCS.

Other Names:
  • Diet
ACTIVE_COMPARATOR: Diet with NCS in dyspepsia
Participants with dyspepsia are assigned to a 5 meals divided diet. In which it contain any products with NCS

A standard diet in terms of macronutrients will be calculated.

  • 55% Carbohydrates
  • 20% protein
  • 25% Lipids The energy calculation will be done with the Harris Benedict formula and a diet with equivalents will be made and then a menu distributed in 5 meals, lasting 7 days.

The menu will contain products with NCS.

Other Names:
  • Diet

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The diet without NCS will change the frequency of gastrointestinal symptoms in patients with IBS.
Time Frame: 12 weeks
Using ROME III criteria, the frequency of patients who present with gastrointestinal symptoms is monitored.
12 weeks
The diet without NCS will change the frequency of gastrointestinal symptoms in patients with dyspepsia.
Time Frame: 12 weeks
Using ROME III criteria, the frequency of patients who present with gastrointestinal symptoms is monitored.
12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The changes in the weight of the patients with irritable bowel syndrome, from the beginning of the diet, at 6 weeks and at 12 weeks
Time Frame: at the week 1, 6 and 12
For the evaluation we are going to use weight in kilograms
at the week 1, 6 and 12
The changes in the weight of the patients with dyspepsia, from the beginning of the diet, at 6 weeks and at 12 weeks
Time Frame: at the week 1, 6 and 12
For the evaluation we are going to use weight in kilograms
at the week 1, 6 and 12
The changes in the body composition in patients with irritable bowel syndrome, from the beginning of the diet, at 6 weeks and at 12 weeks
Time Frame: at the week 1, 6 and 12
We are going to use RJL system IV for body composition we will report the changes in percentage of water, fat and muscle.
at the week 1, 6 and 12
The changes in the body composition in patients with dyspepsia, from the beginning of the diet, at 6 weeks and at 12 weeks
Time Frame: at the week 1, 6 and 12
We are going to use RJL system IV for body composition we will report the changes in percentage of water, fat and muscle.
at the week 1, 6 and 12
The changes in the waist circumference in patients with irritable bowel syndrome, from the beginning of the diet, at 6 weeks and at 12 weeks
Time Frame: at the week 1, 6 and 12
For the evaluation we are going to use waist circumference in centimeters
at the week 1, 6 and 12
The changes in the waist circumference in patients with dyspepsia, from the beginning of the diet, at 6 weeks and at 12 weeks
Time Frame: at the week 1, 6 and 12
For the evaluation we are going to use waist circumference in centimeters
at the week 1, 6 and 12
The changes in glucose in the patients with irritable bowel syndrome, from the beginning and end of the diet
Time Frame: at the week 1 and 12
For the changes we are going to use glucose in mg / dl
at the week 1 and 12
The changes in glucose in the patients with dyspepsia, from the beginning and end of the diet
Time Frame: at the week 1 and 12
For the changes we are going to use glucose in mg / dl
at the week 1 and 12
The changes insulin in the patients with irritable bowel syndrome, at the beginning and end of the diet
Time Frame: at the week 1 and 12
For the serological changes in the insulin we are going to use the measure in IU
at the week 1 and 12
The changes insulin in the patients with dyspepsia, at the beginning and end of the diet
Time Frame: at the week 1 and 12
For the serological changes in the insulin we are going to use the measure in IU
at the week 1 and 12
The changes in the lipids profile in the patients with irritable bowel syndrome, at the beginning and end of the diet
Time Frame: at the week 1 and 12
For the serological changes in the lipid profile we are going to use triglycerides in mg/dl, total cholesterol in mg/dl, HDL in mg/dl, cholesterol, LDL in mg / dl.
at the week 1 and 12
The changes in the lipids profile in the patients with dyspepsia, at the beginning and end of the diet.
Time Frame: at the week 1 and 12
For the serological changes in the lipid profile we are going to use triglycerides in mg/dl, total cholesterol in mg/dl, HDL in mg/dl, cholesterol, LDL in mg / dl.
at the week 1 and 12
Effect of the diet without NCS in gut microbiota in patients with irritable bowel syndrome at the beginning and end of the diet
Time Frame: at the week 1 and 12
Using real-time PCR, the effect of the diet without NCS, on the gut microbiota of patients with irritable bowel syndrome
at the week 1 and 12
Effect of the diet without NCS in gut microbiota in patients with dyspepsia at the beginning and end of the diet
Time Frame: at the week 1 and 12
Using real-time PCR, the effect of the diet without NCS, on the gut microbiota of patients with dyspepsia
at the week 1 and 12

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

July 17, 2019

Primary Completion (ANTICIPATED)

August 31, 2020

Study Completion (ANTICIPATED)

December 31, 2020

Study Registration Dates

First Submitted

October 8, 2019

First Submitted That Met QC Criteria

October 14, 2019

First Posted (ACTUAL)

October 17, 2019

Study Record Updates

Last Update Posted (ACTUAL)

October 17, 2019

Last Update Submitted That Met QC Criteria

October 14, 2019

Last Verified

October 1, 2019

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Functional Gastrointestinal Disorders

Clinical Trials on Diet without NCS

3
Subscribe